CONDUIT PHARMACEUTICALS INC (CDT) Stock Income Statement
NASDAQ:CDT - Nasdaq - US20678X2053 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 16.47M | 15.42M | 5.26M | 3.16M | 3.17M | |||
| Research and Development | 4.56M | 3.38M | 90.00K | 37.00K | 28.00K | |||
| Selling, General, and Administrative Expenses | 11.91M | 12.04M | 5.17M | 3.05M | 2.89M | |||
| Operating Income | -16.47M | -15.42M | -5.26M | -3.16M | -3.17M | |||
| Interest Income/Expense | -1.55M | -1.49M | -196.00K | 1.98M | N/A | |||
| Other Income/Expense | -1.37M | -890.00K | 4.92M | -1.73M | -484.00K | |||
| Income Before Taxes | -19.40M | -17.80M | -535.00K | -4.89M | -3.66M | |||
| Income Tax | N/A | N/A | N/A | 370.00K | N/A | |||
| Net Income | -19.40M | -17.80M | -535.00K | -4.89M | -3.66M | |||
| EBITDA | N/A | -14.96M | N/A | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -164.39 | -307.94 | -0.11 | -1.09 | -0.81 | |||
| Statistics | ||||||||
All data in USD